Pulmonary Fibrosis Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Test Type, End-user, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Pulmonary Fibrosis Biomarkers Market size stood at USD 4.58 Billion in 2026 and is predicted to grow at 4.75% CAGR from 2027 to 2036, attaining USD 7.28 Billion by 2036. The industry revenue for 2027 is assessed at USD 4.76 Billion.
Get more details on this report
Request Free Sample ReportPulmonary Fibrosis Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 43.99% in 2026, supported by advanced healthcare infrastructure, respiratory disease research, and growing adoption of biomarker-based approaches.
- Improving healthcare infrastructure, diagnostic modernization, research investment, and greater awareness of pulmonary disorders are expanding opportunities for biomarker-based disease detection.
Segment Momentum
- Hospitals held a 36.07% market share in 2026 because they provide multidisciplinary respiratory care, advanced diagnostic infrastructure, and integrated imaging, laboratory testing, and specialist consultation for comprehensive patient management.
- Diagnostic laboratories are the fastest-growing end-user segment as increasing demand for specialized biomarker testing, advanced laboratory technologies, and early disease assessment drives wider adoption of laboratory-based diagnostic services.
Market Expansion Drivers
- Rising pulmonary disease burden driving demand for early diagnostic biomarkers
- Advancements in molecular diagnostics accelerating biomarker discovery and validation
- Expanding precision medicine adoption improving biomarker-based treatment stratification
Leading Market Participants
- Major players in the pulmonary fibrosis biomarkers market include F. Hoffmann-La Roche AG (Switzerland), Biogen Inc. (USA), Bristol Myers Squibb Company (USA), Veracyte, Inc. (USA), Myriad Genetics, Inc. (USA), Galapagos NV (Belgium), Biocartis NV (Belgium), Roche Diagnostics International AG (Switzerland), Thermo Fisher Scientific Inc. (USA), Qiagen N.V. (Netherlands)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.58 Billion
- 2027 Estimated Market Size: USD 4.76 Billion
- Projected Market Size: USD 7.28 Billion by 2036
- Growth Forecast: 4.75% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Imaging Test (Test Type) | Hospitals (End-user) | Idiopathic Pulmonary Fibrosis (IPF) (Indication)
- Emerging Opportunity Segment: Imaging Test (Test Type) | Diagnostic Laboratories (End-user) | Idiopathic Pulmonary Fibrosis (IPF) (Indication)
Market Growth Drivers and Industry Trends
Rising pulmonary disease burden driving demand for early diagnostic biomarkers
The increasing incidence of chronic respiratory disorders is creating greater demand for diagnostic tools capable of identifying pulmonary fibrosis at earlier stages of disease progression. As healthcare systems prioritize timely diagnosis to improve clinical management, the pulmonary fibrosis biomarkers market is driven by the growing integration of biomarker-based testing into diagnostic pathways. Clinicians are seeking reliable indicators that can differentiate fibrotic lung conditions from other respiratory diseases, reducing diagnostic uncertainty and enabling earlier therapeutic intervention. The expanding emphasis on disease monitoring and risk assessment is also encouraging broader utilization of biomarker technologies across specialized respiratory care settings.
Advancements in molecular diagnostics accelerating biomarker discovery and validation
Continuous progress in molecular diagnostic technologies is improving the identification and clinical validation of biomarkers associated with pulmonary fibrosis. These innovations will propel the pulmonary fibrosis biomarkers market growth by enabling more precise detection of disease-related molecular signatures and supporting the development of highly sensitive diagnostic assays. Advanced analytical techniques are helping researchers better understand the biological mechanisms underlying fibrosis, while streamlined validation processes are facilitating the transition of promising biomarkers into clinical practice. Enhanced diagnostic accuracy also supports improved patient classification for research and therapeutic decision-making.
Expanding precision medicine adoption improving biomarker-based treatment stratification
The growing adoption of precision medicine is increasing the importance of biomarkers in selecting treatment approaches tailored to individual patient characteristics. This shift will boost the pulmonary fibrosis biomarkers market demand as healthcare providers increasingly rely on molecular information to guide therapeutic decisions and evaluate disease progression. Biomarker-based stratification enables clinicians to identify patient subgroups that may respond differently to available therapies, supporting more personalized clinical management. The integration of biomarker insights into treatment planning also strengthens collaboration between diagnostic laboratories, healthcare providers, and research organizations.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising pulmonary disease burden driving demand for early diagnostic biomarkers | 2% | High | North America, Europe | High | Near Term |
| Advancements in molecular diagnostics accelerating biomarker discovery and validation | 1.7% | High | North America, Asia Pacific | Medium | Mid Term |
| Expanding precision medicine adoption improving biomarker-based treatment stratification | 1.5% | High | Europe, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the pulmonary fibrosis biomarkers market, accounting for 43.99% in 2026. The region's strong position is supported by advanced healthcare infrastructure, substantial research activity in respiratory diseases, and increasing emphasis on earlier and more precise disease identification. Greater adoption of biomarker-based approaches in clinical research and diagnostic development is supporting demand for tools that can improve disease characterization and treatment monitoring. A well-established ecosystem for medical research and advanced diagnostic technologies further contributes to the region's leading market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region, supported by improving healthcare infrastructure, rising awareness of pulmonary disorders, and increasing investment in advanced diagnostic and research capabilities. Expanding access to specialized healthcare services is creating greater opportunities for the adoption of biomarker-based approaches, while the growing burden of chronic respiratory conditions is encouraging stronger attention to early detection and disease management. Improvements in clinical research capabilities and the modernization of diagnostic systems across emerging healthcare markets are also expected to support regional market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Translational Research ExpansionThe U.S. pulmonary fibrosis biomarkers market benefits from extensive clinical research, biomarker validation, and collaboration between healthcare providers and biotechnology companies. Efforts increasingly focus on improving diagnostic precision and supporting personalized treatment decisions.
Germany 🇩🇪
Clinical Validation FocusGermany advances pulmonary fibrosis biomarker adoption through strong clinical research and integration into specialized respiratory care settings. Healthcare institutions prioritize biomarker evidence that supports earlier diagnosis and more informed disease management strategies.
Japan 🇯🇵
Early Detection IntegrationJapan emphasizes pulmonary fibrosis biomarkers that enable earlier identification of disease progression within advanced healthcare systems. Research organizations continue evaluating biomarker applications that enhance clinical decision-making and patient monitoring.
South Korea 🇰🇷
Precision Diagnostic DevelopmentSouth Korea strengthens pulmonary fibrosis biomarker research through investments in molecular diagnostics and precision medicine initiatives. Clinical laboratories increasingly evaluate biomarker panels that improve diagnostic confidence and therapeutic assessment.
France 🇫🇷
Collaborative Clinical ResearchFrance supports pulmonary fibrosis biomarker development through coordinated research efforts linking hospitals, academic institutions, and diagnostic developers. The country prioritizes clinically relevant biomarkers that improve patient stratification and treatment planning.
Italy 🇮🇹
Specialized Respiratory DiagnosticsItaly expands the use of pulmonary fibrosis biomarkers within specialized respiratory care to strengthen diagnostic pathways and disease monitoring. Healthcare providers increasingly integrate biomarker insights alongside imaging and clinical evaluation for comprehensive patient assessment.
Segment Leadership and Growth Trends
Pulmonary Fibrosis Biomarkers Market Share (%), by Test Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTest Type Segment Analysis: Imaging Test (Largest & Fastest-Growing Segment)
The imaging test segment dominated the pulmonary fibrosis biomarkers market with a 43.99% share in 2026 and also represented the fastest-growing test type. Imaging plays a central role in the detection, diagnosis, and ongoing monitoring of pulmonary fibrosis by enabling clinicians to evaluate disease progression and treatment response with greater precision. Continuous improvements in diagnostic imaging technologies and the growing emphasis on early disease identification are supporting sustained adoption of imaging-based assessment methods across healthcare settings.
End-user Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)
The hospitals segment held the largest share of 36.07% in 2026, supported by the availability of multidisciplinary respiratory care, advanced diagnostic infrastructure, and integrated patient management services. Hospitals frequently serve as the primary point of diagnosis and treatment for pulmonary fibrosis, enabling comprehensive evaluation through imaging, laboratory testing, and specialist consultation within a single care environment.
In the pulmonary fibrosis biomarkers market, diagnostic laboratories represent the fastest-growing end-user segment as demand increases for specialized biomarker testing and precise disease assessment. Expanding access to advanced laboratory technologies, greater emphasis on early diagnosis, and rising utilization of specialized diagnostic services are contributing to stronger adoption of laboratory-based biomarker analysis.
Indication Segment Analysis: Idiopathic Pulmonary Fibrosis (IPF) (Largest & Fastest-Growing Segment)
The idiopathic pulmonary fibrosis (IPF) segment accounted for the largest share of 37.8% in 2026 while also emerging as the fastest-growing indication. Its leading position is driven by the significant clinical need for accurate diagnosis and continuous disease monitoring, where biomarker-based approaches play an increasingly important role in supporting treatment decisions. Ongoing advances in biomarker research, growing awareness among healthcare professionals, and increased focus on early identification of progressive lung disorders continue to strengthen the adoption of biomarker testing for patients with idiopathic pulmonary fibrosis.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Test Type | Blood Test, Pulmonary Function Test, Imaging Test, Lung Biopsy, Others | Imaging Test | Imaging Test |
| End-user | Hospitals, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others | Hospitals | Diagnostic Laboratories |
| Indication | Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD), Drug-induced Pulmonary Fibrosis, COVID-19-related Pulmonary Fibrosis, Pneumoconiosis, Sarcoidosis, Others | Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) |
Competitive Landscape and Market Positioning
Prominent players in the pulmonary fibrosis biomarkers market:
- F. Hoffmann-La Roche AG (Switzerland)
- Biogen, Inc. (USA)
- Bristol Myers Squibb Company (USA)
- Veracyte, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- Galapagos NV (Belgium)
- Biocartis NV (Belgium)
- Roche Diagnostics International AG (Switzerland)
- Thermo Fisher Scientific, Inc. (USA)
- Qiagen N.V. (Netherlands)
Scientific differentiation is becoming increasingly important as developers pursue biomarker platforms capable of improving disease detection, patient stratification, and treatment monitoring within pulmonary fibrosis care. Competitive efforts are expanding beyond standalone assays toward integrated diagnostic approaches that combine molecular insights with clinical interpretation, encouraging closer alignment with evolving precision medicine practices. Participants that can demonstrate reproducible analytical performance, compatibility with routine laboratory workflows, and meaningful clinical utility are strengthening their position as healthcare providers seek more informed decision-making throughout the patient management pathway.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche AG (Switzerland) | |||||||
| Biogen Inc. (USA) | |||||||
| Bristol Myers Squibb Company (USA) | |||||||
| Veracyte Inc. (USA) | |||||||
| Myriad Genetics Inc. (USA) | |||||||
| Galapagos NV (Belgium) | |||||||
| Biocartis NV (Belgium) | |||||||
| Roche Diagnostics International AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (USA) | |||||||
| Qiagen N.V. (Netherlands) |
Industry Development/News
| Company Name | Date | Key Development |
|---|
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pulmonary Fibrosis Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Biomarker Type | Protein Biomarkers, Genetic Biomarkers, Autoantibody Biomarkers, Inflammatory Biomarkers, Fibrotic Biomarkers |
| Disease Severity | Mild/early-stage Disease, Moderate Disease, Severe/Advanced Disease |
| Diagnostic Application | Early Disease Detection, Disease Differentiation, Disease Monitoring, Prognosis Assessment, Treatment Response Monitoring |
Pulmonary Fibrosis Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Trial Biomarker Strategy |
|
| Diagnostic Workflow Integration |
|
| Biomarker Commercialization Roadmap |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of pulmonary fibrosis biomarkers?
How will the pulmonary fibrosis biomarkers industry grow in terms of size and CAGR by 2036?
How is precision medicine influencing the pulmonary fibrosis biomarkers market?
Why are advances in molecular diagnostics accelerating adoption of pulmonary fibrosis biomarkers?
Why are hospitals the leading end-user in the pulmonary fibrosis biomarkers market?
Which end-user segment is expanding the fastest in the pulmonary fibrosis biomarkers market?
Why does North America hold the largest pulmonary fibrosis biomarkers market share?
How is Asia Pacific supporting future growth in pulmonary fibrosis biomarkers?
Which organizations are considered leaders in the pulmonary fibrosis biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization